1. 1) Henness S. Pharmacological interventions in the prevention of type 2 diabetes. Curr. Opin. Endocrinol. Diabetes Obes., 14, 166–169 (2007).
2. 2) Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes, 52, 1655–1663 (2003).
3. 3) Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr. Rev., 26, 439–451 (2005).
4. 4) Parker JC. Troglitazone: the discovery and development of a novel therapy for the treatment of type 2 diabetes mellitus. Adv. Drug Deliv. Rev., 54, 1173–1197 (2002).
5. 5) Tsuchida A, Yamauchi T, Kadowaki T. Nuclear receptors as targets for drug development: molecular mechanisms for regulation of obesity and insulin resistance by peroxisome proliferator-activated receptor γ, CREB-binding protein, and adiponectin. J. Pharmacol. Sci., 97, 164–170 (2005).